InterMune gears up for panel review

InterMune announced today that it will meet with an FDA expert panel next Tuesday to review its NDA for pirfenidone. The drug is a treatment for a rare and chronic lung disease called idiopathic pulmonary fibrosis. Report

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.